Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis

Cytoguardin was identified in the conditioned medium of fibroblasts as a tryptophan metabolite, 5-methoxytryptophan (5-MTP). It is synthesized via two enzymatic steps: tryptophan hydroxylase (TPH) and hydroxyindole O-methyltransferase (HIOMT). A truncated HIOMT isoform, HIOMT298, catalyzes 5-MTP syn...

Full description

Bibliographic Details
Main Author: Kenneth K. Wu
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/22/9/4490
id doaj-4a4bccc304864245900cec9de05f26c5
record_format Article
spelling doaj-4a4bccc304864245900cec9de05f26c52021-04-26T23:00:27ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-04-01224490449010.3390/ijms22094490Cytoguardin: A Tryptophan Metabolite against Cancer Growth and MetastasisKenneth K. Wu0Institute of Cellular and System Medicine, National Health Research Institutes, Zhunan Town 35053, TaiwanCytoguardin was identified in the conditioned medium of fibroblasts as a tryptophan metabolite, 5-methoxytryptophan (5-MTP). It is synthesized via two enzymatic steps: tryptophan hydroxylase (TPH) and hydroxyindole O-methyltransferase (HIOMT). A truncated HIOMT isoform, HIOMT298, catalyzes 5-MTP synthesis. Cancer cells produce scarce 5-MTP due to defective HIOMT298 expression. 5-MTP inhibits cancer cell COX-2 expression and thereby reduces COX-2-mediated cell proliferation and migration. 5-MTP also inhibits MMP-9 expression and thereby reduces cancer cell invasion. 5-MTP exerts its anti-cancer effect by blocking p38 MAPK and p38-mediated NF-κB and p300 HAT activation. The stable transfection of A549 cells with HIOMT298 restores 5-MTP production which renders cancer cells less aggressive. The implantation of HIOMT-transfected A549 into subcutaneous tissues of a murine xenograft tumor model shows that HIOMT-transduced A549 cells form smaller tumors and generate fewer metastatic lung nodules than control A549 cells. HIOMT298 transfection suppresses aromatic amino acid decarboxylase (AADC) expression and serotonin production. Serotonin is a cancer-promoting factor. By restoring 5-MTP and suppressing serotonin production, HIOMT298 overexpression converts cancer cells into less malignant phenotypes. The analysis of HIOMT expression in a human cancer tissue array showed reduced HIOMT levels in a majority of colorectal, pancreatic, and breast cancer. HIOMT298 may be a biomarker of human cancer progression. Furthermore, 5-MTP has the potential to be a lead compound in the development of new therapy for the chemoprevention of certain cancers such as hepatocellular cancer.https://www.mdpi.com/1422-0067/22/9/4490cytoguardin5-methoxytryptophancancer growthcancer metastasiscyclooxygenase-2matrix metalloproteinase
collection DOAJ
language English
format Article
sources DOAJ
author Kenneth K. Wu
spellingShingle Kenneth K. Wu
Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis
International Journal of Molecular Sciences
cytoguardin
5-methoxytryptophan
cancer growth
cancer metastasis
cyclooxygenase-2
matrix metalloproteinase
author_facet Kenneth K. Wu
author_sort Kenneth K. Wu
title Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis
title_short Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis
title_full Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis
title_fullStr Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis
title_full_unstemmed Cytoguardin: A Tryptophan Metabolite against Cancer Growth and Metastasis
title_sort cytoguardin: a tryptophan metabolite against cancer growth and metastasis
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-04-01
description Cytoguardin was identified in the conditioned medium of fibroblasts as a tryptophan metabolite, 5-methoxytryptophan (5-MTP). It is synthesized via two enzymatic steps: tryptophan hydroxylase (TPH) and hydroxyindole O-methyltransferase (HIOMT). A truncated HIOMT isoform, HIOMT298, catalyzes 5-MTP synthesis. Cancer cells produce scarce 5-MTP due to defective HIOMT298 expression. 5-MTP inhibits cancer cell COX-2 expression and thereby reduces COX-2-mediated cell proliferation and migration. 5-MTP also inhibits MMP-9 expression and thereby reduces cancer cell invasion. 5-MTP exerts its anti-cancer effect by blocking p38 MAPK and p38-mediated NF-κB and p300 HAT activation. The stable transfection of A549 cells with HIOMT298 restores 5-MTP production which renders cancer cells less aggressive. The implantation of HIOMT-transfected A549 into subcutaneous tissues of a murine xenograft tumor model shows that HIOMT-transduced A549 cells form smaller tumors and generate fewer metastatic lung nodules than control A549 cells. HIOMT298 transfection suppresses aromatic amino acid decarboxylase (AADC) expression and serotonin production. Serotonin is a cancer-promoting factor. By restoring 5-MTP and suppressing serotonin production, HIOMT298 overexpression converts cancer cells into less malignant phenotypes. The analysis of HIOMT expression in a human cancer tissue array showed reduced HIOMT levels in a majority of colorectal, pancreatic, and breast cancer. HIOMT298 may be a biomarker of human cancer progression. Furthermore, 5-MTP has the potential to be a lead compound in the development of new therapy for the chemoprevention of certain cancers such as hepatocellular cancer.
topic cytoguardin
5-methoxytryptophan
cancer growth
cancer metastasis
cyclooxygenase-2
matrix metalloproteinase
url https://www.mdpi.com/1422-0067/22/9/4490
work_keys_str_mv AT kennethkwu cytoguardinatryptophanmetaboliteagainstcancergrowthandmetastasis
_version_ 1721507349454127104